Oryzon Genomics S.A (ORY) | Stock Overview & Key Data
Oryzon Genomics S.A. | Mid-cap | Healthcare
Oryzon Genomics S.A. | Mid-cap | Healthcare
Oryzon Genomics S.A Performance Comparison
Stock Range
Today's Range
Low: €2.61
High: €2.67
on August 4, 2025
52 Week Range
Low: €1.40
High: €3.69
on January 27, 2025
on February 24, 2025
All-Time High: €5.25 on December 14, 2015
Explore how other Spanish stocks compare to their 52-week ranges: View ES Market 52-Week Insights
Key Statistics
Market Cap
€202.3M
EPS
-0.06
P/E Ratio (TTM)
-44.28
Forward P/E
-15.35
P/B Ratio
1.94
PEG Ratio
-15.35
Div. Yield
N/A
ROE
-4.20%
Beta
N/A
Debt to Equity
15.22
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
6.30%
Profit Margin
-56.48%
Returns and Earnings
Return on Assets (TTM)
-2.52%
Return on Equity (TTM)
-4.20%
EBITDA
€-4.9M
Net Income (TTM)
€-4.2M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€0.12
Quarterly Revenue Growth (YoY)
2.70%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Oryzon Genomics S.A ORY | 202.31M Mid-cap | -5.09% | -2.61% | -1.88% | 82.52% | 74.00% | 45.81% | 3.16% | -3.33% |
| Pharma Mar S.A PHM | 1.38B Large-cap | -4.11% | -0.06% | 4.90% | -12.96% | -1.00% | 106.70% | 28.61% | -8.80% |
| Atrys Health S.A ATRY | 217.06M Mid-cap | -4.35% | 10.00% | -0.69% | -18.29% | -18.29% | -8.63% | -55.03% | -61.35% |
| Vytrus Biotech S.A VYT | 42.89M Small-cap | 0.00% | 35.71% | 72.73% | 156.76% | 163.89% | 77.57% | 83.87% | 102.13% |
| Biotechnology Assets BST | 23.82M Small-cap | -2.78% | -14.63% | 20.69% | 9.38% | 25.00% | 9.38% | 84.21% | -58.33% |
| Grifols, S.A GRF | 7.85B Large-cap | 5.04% | 24.21% | 51.58% | 58.65% | 36.68% | 45.94% | -8.10% | -47.67% |
Ownership & Short Interest
Insider Ownership
21.27%
Institutional Ownership
4.20%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
436K
Average 90-Day Volume
449K
Oryzon Genomics S.A Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Oryzon Genomics S.A would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ORY's 52-week high and low?
- In the last 52 weeks, Oryzon Genomics S.A reached a high of €3.69 (on February 24, 2025) and a low of €1.40 (on January 27, 2025).
- What is the market cap and P/E ratio for ORY?
- Curious about Oryzon Genomics S.A's size and valuation? Its market capitalization stands at 202.31M. When it comes to valuation, the P/E ratio (trailing twelve months) is -44.28, and the forward P/E (looking ahead) is -15.35.
- Does ORY pay dividends? If so, what's the yield?
- As for dividends, Oryzon Genomics S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Oryzon Genomics S.A's main competitors or similar companies to consider before investing?
When looking at Oryzon Genomics S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Pharma Mar S.A
PHM1.38B Healthcare Biotechnology 106.70% 28.61% Atrys Health S.A
ATRY217.06M Healthcare Biotechnology -8.63% -55.03% Vytrus Biotech S.A
VYT42.89M Healthcare Biotechnology 77.57% 83.87% Biotechnology Assets
BST23.82M Healthcare Biotechnology 9.38% 84.21% Grifols, S.A
GRF7.85B Healthcare Drug Manufacturers - General 45.94% -8.10% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Oryzon Genomics S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Oryzon Genomics S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -4.20%, the Debt to Equity ratio from the most recent quarter is 15.22, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for ORY?
- Looking at Oryzon Genomics S.A's growth, its revenue over the trailing twelve months (TTM) was €7M. Compared to the same quarter last year (YoY), quarterly revenue grew by 2.70%, and quarterly earnings saw a YoY growth of N/A.
- How much of ORY stock is held by insiders and institutions?
- Wondering who owns Oryzon Genomics S.A stock? Company insiders (like executives and directors) hold about 21.27% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 4.20%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.